» Articles » PMID: 30404933

The Fourth International Neonatal and Maternal Immunization Symposium (INMIS 2017): Toward Integrating Maternal and Infant Immunization Programs

Overview
Journal mSphere
Date 2018 Nov 9
PMID 30404933
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Prevention of serious infections in pregnant mothers, newborns, and young infants through immunization during pregnancy and in early life has the potential to further reduce maternal and neonatal morbidity and mortality worldwide. In the past decade, research in this field has advanced substantially, from the understanding of the biology and immunology of pregnancy and early life, to the active development of several candidate vaccines, for which challenges and opportunities for global implementation are under consideration. Experts from academia, industry, regulatory and funding agencies, public health, and international organizations met in Brussels (Belgium) from 10 to 12 September 2017, at the 4th International Neonatal and Maternal Immunization Symposium (INMIS), to review the most relevant advances in maternal and neonatal immunization. The overarching focus of the conference was to identify the path forward to achieve integration of maternal and early life immunization strategies for the successful implementation of vaccines in antenatal care and pediatric programs for reduction of maternal and infant mortality worldwide. This report provides an overview of the proceedings of the 4th International Maternal and Neonatal Immunization Symposium, where presentations focused on the state-of-the-art research on the development and implementation of vaccines given during pregnancy for the protection of mothers and infants.

Citing Articles

Maternal Immunization: Nature Meets Nurture.

Saso A, Kampmann B Front Microbiol. 2020; 11:1499.

PMID: 32849319 PMC: 7396522. DOI: 10.3389/fmicb.2020.01499.


Obstetrics risk Assessment: Evaluation of selection criteria for vaccine research studies in pregnant women.

Eckert L, Jones C, Kachikis A, Bardaji A, Da Silva F, Absalon J Vaccine. 2020; 38(29):4542-4547.

PMID: 32448618 PMC: 7211583. DOI: 10.1016/j.vaccine.2020.05.022.


Use of a Neonatal-Mouse Model to Characterize Vaccines and Strategies for Overcoming the High Susceptibility and Severity of Pertussis in Early Life.

Martin Aispuro P, Ambrosis N, Zurita M, Gaillard M, Bottero D, Hozbor D Front Microbiol. 2020; 11:723.

PMID: 32362890 PMC: 7182080. DOI: 10.3389/fmicb.2020.00723.


Immunization: vital progress, unfinished agenda.

Piot P, Larson H, OBrien K, Nkengasong J, Ng E, Sow S Nature. 2019; 575(7781):119-129.

PMID: 31695203 DOI: 10.1038/s41586-019-1656-7.

References
1.
Voysey M, Pollard A, Sadarangani M, Fanshawe T . Prevalence and decay of maternal pneumococcal and meningococcal antibodies: A meta-analysis of type-specific decay rates. Vaccine. 2017; 35(43):5850-5857. PMC: 5628610. DOI: 10.1016/j.vaccine.2017.09.002. View

2.
Ojal J, Goldblatt D, Tigoi C, Scott J . Effect of Maternally Derived Anti-protein and Anticapsular IgG Antibodies on the Rate of Acquisition of Nasopharyngeal Carriage of Pneumococcus in Newborns. Clin Infect Dis. 2017; 66(1):121-130. PMC: 5850545. DOI: 10.1093/cid/cix742. View

3.
Kollmann T, Kampmann B, Mazmanian S, Marchant A, Levy O . Protecting the Newborn and Young Infant from Infectious Diseases: Lessons from Immune Ontogeny. Immunity. 2017; 46(3):350-363. DOI: 10.1016/j.immuni.2017.03.009. View

4.
van Hoek A, Campbell H, Amirthalingam G, Andrews N, Miller E . Cost-effectiveness and programmatic benefits of maternal vaccination against pertussis in England. J Infect. 2016; 73(1):28-37. DOI: 10.1016/j.jinf.2016.04.012. View

5.
Spijkerman J, Veenhoven R, Wijmenga-Monsuur A, Elberse K, van Gageldonk P, Knol M . Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial. JAMA. 2013; 310(9):930-7. DOI: 10.1001/jama.2013.228052. View